Pazopanib: therapeutic developments
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/14656560903436493
Reference72 articles.
1. The biology of VEGF and its receptors
2. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
3. Antiangiogenesis and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Targeting as Part of a Combined-Modality Approach to the Treatment of Cancer
4. Cell Signaling by Receptor Tyrosine Kinases
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pazopanib stimulates senescence of renal carcinoma cells through targeting nuclear factor E2‐related factor 2 (Nrf2);Journal of Biochemical and Molecular Toxicology;2024-04
2. Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice;Cancers;2024-01-13
3. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer;Frontiers in Immunology;2023-10-23
4. Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib;Anticancer Research;2023-01-25
5. Pazopanib alleviates neuroinflammation and protects dopaminergic neurons in LPS-stimulated mouse model by inhibiting MEK4-JNK-AP-1 pathway;Acta Pharmacologica Sinica;2022-12-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3